Search

Your search keyword '"Tauopathies cerebrospinal fluid"' showing total 21 results

Search Constraints

Start Over You searched for: Descriptor "Tauopathies cerebrospinal fluid" Remove constraint Descriptor: "Tauopathies cerebrospinal fluid" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
21 results on '"Tauopathies cerebrospinal fluid"'

Search Results

1. Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.

2. Neuromodulatory subcortical nucleus integrity is associated with white matter microstructure, tauopathy and APOE status.

3. Proteomic changes in the human cerebrovasculature in Alzheimer's disease and related tauopathies linked to peripheral biomarkers in plasma and cerebrospinal fluid.

4. Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies.

5. MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology.

6. Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease.

7. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias.

8. Sleep-Wake Cycle in Alzheimer's Disease Is Associated with Tau Pathology and Orexin Dysregulation.

9. Biomarkers for tau pathology.

10. Diagnostic performance of new and classic CSF biomarkers in age-related dementias.

11. Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy.

12. Metabolic status of CSF distinguishes rats with tauopathy from controls.

13. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.

14. Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid.

15. Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders.

16. Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.

17. Changes of Cerebrospinal Fluid Peptides due to Tauopathy.

18. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

19. Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.

21. Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.

Catalog

Books, media, physical & digital resources